What the FDA labels say about taking them together
Methotrexate and pegloticase
Pegloticase's FDA label of July 9, 2026 names methotrexate in its drug interactions section; the methotrexate labels PlainMeds reads (4) do not name pegloticase. The pegloticase label: “Co-administration of methotrexate with KRYSTEXXA may increase pegloticase concentration compared to KRYSTEXXA alone.”
Check it at the source: the methotrexate FDA label on DailyMed (effective May 27, 2026, Accord Healthcare Inc.); the pegloticase FDA label on DailyMed (effective July 9, 2026, Horizon Therapeutics USA, Inc.).
What does the methotrexate label say about pegloticase?
Methotrexate's label (effective May 27, 2026) and its 3 other brand-application labels do not name pegloticase in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Methotrexate), Accord Healthcare Inc., effective May 27, 2026 (SPL set 874c7f43-a3be-4236-89cc-24c44e3c5813), via openFDA; the full label on DailyMed
What does the pegloticase label say about methotrexate?
Pegloticase label, drug interactionsCo-administration of methotrexate with KRYSTEXXA may increase pegloticase concentration compared to KRYSTEXXA alone [see Clinical Pharmacology (12.3) ].
Pegloticase label, warnings and precautionsIn a 52-week controlled trial, which evaluated KRYSTEXXA co-administered with methotrexate compared to KRYSTEXXA alone, subjects were pre-treated with standardized infusion reaction prophylaxis and were discontinued from treatment with KRYSTEXXA if serum uric acid levels increased to above 6 mg/dL at 2 consecutive visits after the initiation of KRYSTEXXA therapy to reduce the risk of anaphylaxis.
Source: FDA drug label (Krystexxa), Horizon Therapeutics USA, Inc., effective July 9, 2026 (SPL set 6e566303-d93a-4130-b764-25749829aa95), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Methotrexate | Pegloticase | |
|---|---|---|
| Labeled for | Rheumatoid arthritis, Psoriasis, Leukemia, lymphoma and myeloma, Breast cancer | Gout |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.158 per tablet 2.5 mg tablet | n/a |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once